Form 8-K Vir Biotechnology, Inc. For: Jun 05
![SEC EDGAR](../../../Content/images/providers/SC.png)
Vir Biotechnology, Inc. (VIR)
Company Research
Source: SEC EDGAR
![SEC EDGAR](../../../Content/images/providers/SC.png)
Impact Snapshot
Event Time:
VIR
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
---|---|---|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
Last Price | ||
VWAP | ||
High:
|
Max Up |
High:
|
Low:
|
Max Down |
Low:
|
%
|
Post news range |
%
|
|
Price change |
|
|
Price Change Percentage |
|
|
S&P 500 (SPX) |
|
%
|
Volume ratio |
%
|
Volume | ||
Ticks | ||
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
VIR alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
VIR alerts
High impacting Vir Biotechnology, Inc. news events
Weekly update
A roundup of the hottest topics
VIR
News
- Vir Biotechnology Receives FDA IND Clearance and Fast Track Designation for Tobevibart and Elebsiran for the Treatment of Chronic Hepatitis Delta Infection [Yahoo! Finance]Yahoo! Finance
- Vir Biotechnology Receives FDA IND Clearance and Fast Track Designation for Tobevibart and Elebsiran for the Treatment of Chronic Hepatitis Delta InfectionBusiness Wire
- Is Vir Biotechnology (NASDAQ:VIR) In A Good Position To Deliver On Growth Plans? [Yahoo! Finance]Yahoo! Finance
- Vir Biotechnology (VIR) Up on Positive Data From HDV Study [Yahoo! Finance]Yahoo! Finance
- Vir Biotechnology, Inc. (NASDAQ: VIR) had its price target raised by analysts at Morgan Stanley from $12.00 to $15.00. They now have an "equal weight" rating on the stock.MarketBeat
VIR
Earnings
- 5/2/24 - Beat
VIR
Sec Filings
- 6/26/24 - Form 8-K
- 6/12/24 - Form 4
- 6/12/24 - Form 4
- VIR's page on the SEC website